🚀 VC round data is live in beta, check it out!
Savior Lifetec Valuation Multiples
Discover revenue and EBITDA valuation multiples for Savior Lifetec and similar public comparables like Mycenax Biotech, Karyopharm Therapeutics, Whitehawk Therapeutics, Tonix Pharmaceuticals and more.
Savior Lifetec Overview
About Savior Lifetec
Savior Lifetec Corp is engaged in the research, development, design, manufacture, and sale of carbapenem generics, injection generics, controlled-release generics, development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms of the aforementioned products. The company also provides medicine manufacturer technology and services. The company geographically operates in four regions: the Americas, Asia, Taiwan, and Europe.
Founded
2004
HQ
Employees
285
Website
Financials (FY)
EV
$150M
Savior Lifetec Financials
Savior Lifetec reported last fiscal year revenue of $38M and EBITDA of $20M.
In the same fiscal year, Savior Lifetec generated $13M in gross profit, $20M in EBITDA, and $17M in net income.
Savior Lifetec P&L
In the most recent fiscal year, Savior Lifetec reported revenue of $38M and EBITDA of $20M.
Savior Lifetec expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $38M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $13M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 35% | XXX | XXX | XXX |
| EBITDA | — | XXX | $20M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 53% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 16% | XXX | XXX | XXX |
| Net Profit | — | XXX | $17M | XXX | XXX | XXX |
| Net Margin | — | XXX | 45% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Savior Lifetec Stock Performance
Savior Lifetec has current market cap of $196M, and enterprise value of $150M.
Market Cap Evolution
Savior Lifetec's stock price is $0.63.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $150M | $196M | 0.1% | XXX | XXX | XXX | $0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSavior Lifetec Valuation Multiples
Savior Lifetec trades at 4.0x EV/Revenue multiple, and 7.5x EV/EBITDA.
Savior Lifetec Financial Valuation Multiples
As of April 19, 2026, Savior Lifetec has market cap of $196M and EV of $150M.
Equity research analysts estimate Savior Lifetec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Savior Lifetec has a P/E ratio of 11.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $196M | XXX | $196M | XXX | XXX | XXX |
| EV (current) | $150M | XXX | $150M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 7.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 24.0x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 11.2x | XXX | XXX | XXX |
| P/E | — | XXX | 11.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (28.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Savior Lifetec Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Savior Lifetec Margins & Growth Rates
Savior Lifetec's revenue in the last fiscal year declined by (1%).
Savior Lifetec's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Savior Lifetec Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 53% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 101% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Savior Lifetec Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Savior Lifetec | XXX | XXX | XXX | XXX | XXX | XXX |
| Mycenax Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Karyopharm Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Whitehawk Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tonix Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Hyloris Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Savior Lifetec M&A Activity
Savior Lifetec acquired XXX companies to date.
Last acquisition by Savior Lifetec was on XXXXXXXX, XXXXX. Savior Lifetec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Savior Lifetec
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSavior Lifetec Investment Activity
Savior Lifetec invested in XXX companies to date.
Savior Lifetec made its latest investment on XXXXXXXX, XXXXX. Savior Lifetec invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Savior Lifetec
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Savior Lifetec
| When was Savior Lifetec founded? | Savior Lifetec was founded in 2004. |
| Where is Savior Lifetec headquartered? | Savior Lifetec is headquartered in Taiwan. |
| How many employees does Savior Lifetec have? | As of today, Savior Lifetec has over 285 employees. |
| Is Savior Lifetec publicly listed? | Yes, Savior Lifetec is a public company listed on Taipei Exchange. |
| What is the stock symbol of Savior Lifetec? | Savior Lifetec trades under 4167 ticker. |
| When did Savior Lifetec go public? | Savior Lifetec went public in 2015. |
| Who are competitors of Savior Lifetec? | Savior Lifetec main competitors are Mycenax Biotech, Karyopharm Therapeutics, Whitehawk Therapeutics, Tonix Pharmaceuticals. |
| What is the current market cap of Savior Lifetec? | Savior Lifetec's current market cap is $196M. |
| What is the current revenue of Savior Lifetec? | Savior Lifetec's last fiscal year revenue is $38M. |
| What is the current EV/Revenue multiple of Savior Lifetec? | Current revenue multiple of Savior Lifetec is 4.0x. |
| Is Savior Lifetec profitable? | No, Savior Lifetec is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.